bucladesine has been researched along with Granulocytic Leukemia, Chronic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kan, WM; Xiao, LY | 1 |
| Savage, N; Weitzmann, MN | 1 |
| Goel, R; Kaul, D; Varma, S | 1 |
3 other study(ies) available for bucladesine and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Cyclic AMP (cAMP) confers drug resistance against DNA damaging agents via PKAIA in CML cells.
Topics: Bucladesine; Cell Death; Cisplatin; Colforsin; Cyclic AMP; Cyclic AMP-Dependent Protein Kinase Type I; DNA Damage; Drug Resistance, Neoplasm; Etoposide; Humans; Intracellular Space; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Signal Transduction | 2017 |
Cyclic adenosine 3',5'-monophosphate, a second messenger in interleukin-1 mediated K562 cytostasis.
Topics: Adenylyl Cyclases; Alkaloids; Bucladesine; Cell Division; Colforsin; Cyclic AMP; Humans; Interleukin-1; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Second Messenger Systems; Staurosporine; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1993 |
Sterol dependent LDL-receptor gene transcription in lymphocytes from normal and CML patients.
Topics: Bucladesine; Dibutyryl Cyclic GMP; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Phosphorylation; Receptors, LDL; Sterols; Transcription Factors; Transcription, Genetic; Zinc | 1996 |